This company has been marked as potentially delisted and may not be actively trading. Vermillion (VRML) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VRML vs. VNRX, NAVB, FTLF, BTMD, CRBU, KYTX, MIST, CLLS, TVGN, and VTYXShould you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include VolitionRx (VNRX), Navidea Biopharmaceuticals (NAVB), FitLife Brands (FTLF), biote (BTMD), Caribou Biosciences (CRBU), Kyverna Therapeutics (KYTX), Milestone Pharmaceuticals (MIST), Cellectis (CLLS), Tevogen Bio (TVGN), and Ventyx Biosciences (VTYX). These companies are all part of the "medical" sector. Vermillion vs. Its Competitors VolitionRx Navidea Biopharmaceuticals FitLife Brands biote Caribou Biosciences Kyverna Therapeutics Milestone Pharmaceuticals Cellectis Tevogen Bio Ventyx Biosciences VolitionRx (NYSE:VNRX) and Vermillion (NASDAQ:VRML) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability. Is VNRX or VRML more profitable? Vermillion has a net margin of -307.31% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Vermillion's return on equity.Company Net Margins Return on Equity Return on Assets VolitionRx-2,321.14% N/A -163.39% Vermillion -307.31%-155.25%-103.47% Does the media prefer VNRX or VRML? In the previous week, VolitionRx had 3 more articles in the media than Vermillion. MarketBeat recorded 3 mentions for VolitionRx and 0 mentions for Vermillion. VolitionRx's average media sentiment score of 0.20 beat Vermillion's score of 0.00 indicating that VolitionRx is being referred to more favorably in the media. Company Overall Sentiment VolitionRx Neutral Vermillion Neutral Which has more risk & volatility, VNRX or VRML? VolitionRx has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Vermillion has a beta of 3.47, suggesting that its share price is 247% more volatile than the S&P 500. Which has stronger earnings and valuation, VNRX or VRML? Vermillion has higher revenue and earnings than VolitionRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolitionRx$1.32M50.81-$35.32M-$0.25-2.49Vermillion$4.54M10.25-$15.24MN/AN/A Do analysts recommend VNRX or VRML? VolitionRx presently has a consensus target price of $3.50, suggesting a potential upside of 461.80%. Given VolitionRx's stronger consensus rating and higher probable upside, analysts plainly believe VolitionRx is more favorable than Vermillion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Vermillion 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of VNRX or VRML? 8.1% of VolitionRx shares are held by institutional investors. Comparatively, 18.1% of Vermillion shares are held by institutional investors. 10.4% of VolitionRx shares are held by company insiders. Comparatively, 4.4% of Vermillion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryVolitionRx beats Vermillion on 10 of the 16 factors compared between the two stocks. Get Vermillion News Delivered to You Automatically Sign up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRML vs. The Competition Export to ExcelMetricVermillionDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.55M$22.46M$5.70B$10.39BDividend YieldN/AN/A5.78%4.70%P/E Ratio-2.81N/A75.6026.38Price / Sales10.2517.78536.29234.17Price / CashN/AN/A25.6730.68Price / Book5.31N/A12.826.40Net Income-$15.24M-$19.12M$3.29B$276.69M Vermillion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRMLVermillionN/A$0.48-16.1%N/A-42.1%$46.55M$4.54M-2.8143Gap DownVNRXVolitionRx2.0487 of 5 stars$0.64+1.6%$3.50+446.8%+4.7%$68.87M$1.32M-1.7880News CoverageAnalyst ForecastNAVBNavidea BiopharmaceuticalsN/A$0.00-80.0%N/A-80.0%$10K$8.13K0.0010Gap DownHigh Trading VolumeFTLFFitLife Brands4.0184 of 5 stars$18.56+1.9%$23.00+23.9%+19.7%$171.01M$64.47M22.1020Positive NewsBTMDbiote2.9485 of 5 stars$3.39-1.7%$6.00+77.0%-47.3%$170.56M$197.19M3.77194Positive NewsCRBUCaribou Biosciences2.5687 of 5 stars$1.80-1.6%$6.67+270.4%+7.6%$170.42M$9.99M-1.01100Gap UpKYTXKyverna Therapeutics2.6749 of 5 stars$3.87-1.0%$16.60+328.9%+16.6%$169.09M$7.03M-1.0596MISTMilestone Pharmaceuticals2.623 of 5 stars$1.95-1.0%$4.50+130.8%+30.7%$167.44M$1M-2.3230CLLSCellectis3.2268 of 5 stars$3.16+5.7%$4.00+26.6%+53.8%$166.20M$49.22M-3.85290Positive NewsGap DownTVGNTevogen Bio2.5559 of 5 stars$0.85+0.9%$10.00+1,076.5%+100.1%$165.65MN/A-4.473VTYXVentyx Biosciences2.7284 of 5 stars$2.33+1.3%$7.50+221.9%+29.0%$164.01MN/A-1.3930 Related Companies and Tools Related Companies VolitionRx Competitors Navidea Biopharmaceuticals Competitors FitLife Brands Competitors biote Competitors Caribou Biosciences Competitors Kyverna Therapeutics Competitors Milestone Pharmaceuticals Competitors Cellectis Competitors Tevogen Bio Competitors Ventyx Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRML) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vermillion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vermillion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRML Stock Alerts